Effect of Targeted Therapy with Bevacizumab Combined with Conventional Chemotherapy in the Treatment of Patients with Advanced Colorectal Cancer
Objective:To explore the effect of targeted therapy with Bevacizumab and conventional chemotherapy in the treatment of patients with advanced colorectal cancer.Method:A total of 84 patients with advanced colorectal cancer who admitted to Linyi Traditional Chinese Medicine Hospital from August 2020 to August 2021 were selected as the study objects,the patients were divided into control group(n=42)and observation group(n=42)according to the random number table method.The control group was given routine chemotherapy,while the observation group was given targeted therapy with Bevacizumab on the basis of the control group.The clinical efficacy,serum matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor(VEGF),tumor markers[carbohydrate antigen 19-9(CA19-9),tumor associated mucus antigen(CA242)],survival time and adverse reactions were compared between two groups.Result:The total effective rate of treatment in the observation group was 64.29%,which was higher than 42.86%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum MMP-9,VEGF,CA19-9 and CA242 in two groups were lower than those before treatment,and those in the observation group were lower than those in the control group,the progression-free survival(PFS)and overall survival(OS)of the observation group were longer than those of the control group,the 2-year survival rate was 83.33%,which was higher than 57.14%of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The use of targeted therapy with Bevacizumab combined with conventional chemotherapy in patients with advanced colorectal cancer has a significant effect,which can help to enhance the body's immunity,inhibit tumor growth,restore tumor markers to normal,prolong survival,and is safe.
Advanced colorectal cancerTargeted therapy with BevacizumabChemotherapyMatrix metalloproteinase-9Vascular endothelial growth factorTumor markersDuration of life
万方数据
维普
